Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician's choice chemotherapy treatment (PCT): A focus on the EMBRACA triple negative (TNBC) subpopulation

被引：0
|
作者：
Rugo, H. S. [1 ]
Quek, R. [2 ]
Ettl, J. [3 ]
Hurvitz, S. A. [4 ]
Bhattacharyya, H. [2 ]
Hannah, A. L. [5 ]
Litton, J. K. [6 ]
机构：
[1] UCSF Helen Diller Family Comprehens Canc Ctr, Breast Canc Ctr, San Francisco, CA USA
[2] Pfizer Inc, Hlth Econ, San Francisco, CA USA
[3] Tech Univ Munich, Obs Gyn, Munich, Germany
[4] Univ Calif Los Angeles, Hematol Oncol, Santa Monica, CA USA
[5] Pfizer Inc, Oncol, San Francisco, CA USA
[6] Univ Texas MD Anderson Canc Ctr, Breast Med Oncol, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
292O
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial
    Hurvitz, S. A.
    Quek, R. G. W.
    Turner, N. C.
    Telli, M. L.
    Rugo, H. S.
    Mailliez, A.
    Ettl, J.
    Grischke, E.
    Mina, L. A.
    Balmana, J.
    Fasching, P. A.
    Bhattacharyya, H.
    Hannah, A. L.
    Robson, M. E.
    Wardley, A. M.
    EUROPEAN JOURNAL OF CANCER, 2018, 104 : 160 - 168
  • [32] Impact of race on clinical outcomes among patients with advanced triple negative breast cancer (TNBC) and Germline BRCA1/2 mutation(s) (gBRCA1/2mut): Results from a US real-world study
    Whitaker, Kristen
    Parikh, Rohan
    Esterberg, Elizabeth
    Arondekar, Bhakti
    Hitchens, Abigail
    Arruda, Lillian Shahied
    Niyazov, Alexander
    Obeid, Elias
    CANCER RESEARCH, 2022, 82 (04)
  • [33] Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): Efficacy in patients with visceral metastases
    Tung, Nadine M.
    Im, Seock-Ah
    Senkus-Konefka, Elzbieta
    Xu, Binghe
    Domchek, Susan M.
    Masuda, Norikazu
    Li, Wei
    Armstrong, Anne Caroline
    Conte, Pier Franco
    Wu, Wenting
    Goessl, Carsten Dietrich
    Runswick, Sarah
    Robson, Mark E.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [34] Neoadjuvant talazoparib (TALA) in patients (pts) with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Exploration of tumor BRCA mutational status and zygosity and overall mutational landscape in a phase 2 study.
    Telli, Melinda L.
    Litton, Jennifer Keating
    Beck, Joseph Thaddeus
    Jones, Jason M.
    Andersen, Jay
    Mina, Lida A.
    Brig, Raymond
    Danso, Michael A.
    Yuan, Yuan
    Symmans, William Fraser
    Abbattista, Antonello
    Noonan, Kay
    Mata, Marielena
    Laird, Douglas
    Blum, Joanne Lorraine
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
    Robson, M. E.
    Tung, N.
    Conte, P.
    Im, S-A
    Senkus, E.
    Xu, B.
    Masuda, N.
    Delaloge, S.
    Li, W.
    Armstrong, A.
    Wu, W.
    Goessl, C.
    Runswick, S.
    Domchek, S. M.
    ANNALS OF ONCOLOGY, 2019, 30 (04) : 558 - 566
  • [36] The Talazoparib Beyond BRCA (TBB) trial: A phase II clinical trial of talazoparib (BMN 673) in BRCA1 and BRCA2 wild-type patients with (i) advanced triple negative breast cancer (TNBC) and homologous recombination deficiency (HRD) as assessed by myriad genetics HRD assay, and (ii) advanced HER2-negative breast cancer (BC) with either a germline or somatic mutation in homologous recombination (HR) pathway genes
    Afghahi, A.
    Chang, P-J
    Ford, J. M.
    Telli, M. L.
    CANCER RESEARCH, 2016, 76
  • [37] OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician?s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
    Robson, Mark E.
    Im, Seock-Ah
    Senkus, Elzbieta
    Xu, Binghe
    Domchek, Susan M.
    Masuda, Norikazu
    Delaloge, Suzette
    Tung, Nadine
    Armstrong, Anne
    Dymond, Mike
    Fielding, Anitra
    Allen, Allison
    Conte, Pierfranco
    EUROPEAN JOURNAL OF CANCER, 2023, 184 : 39 - 47
  • [38] OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
    Robson, Mark
    Im, Seock-Ah
    Senkus, Elzbieta
    Xu, Binghe
    Domchek, Susan
    Masuda, Norikazu
    Delaloge, Suzette
    Li, Wei
    Tung, Nadine
    Armstrong, Anne
    Bannister, Wendy
    Goessl, Carsten
    Allen, Allison
    Conte, Pierfranco
    CANCER RESEARCH, 2020, 80 (04)
  • [39] Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2–negative advanced breast cancer from the United States, Europe, and Israel
    Reshma Mahtani
    Alexander Niyazov
    Bhakti Arondekar
    Katie Lewis
    Alex Rider
    Lucy Massey
    Michael Patrick Lux
    BMC Cancer, 22
  • [40] Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from the United States, Europe, and Israel
    Mahtani, Reshma
    Niyazov, Alexander
    Arondekar, Bhakti
    Lewis, Katie
    Rider, Alex
    Massey, Lucy
    Lux, Michael Patrick
    BMC CANCER, 2022, 22 (01)
12345